text:
Participating Organization(s)
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Funding Opportunity Title
Clinical Coordinating Center (CCC) for the NHLBI Prevention and Early Treatment of Acute Lung Injury (PETAL) Clinical Trials Network (U01)
Activity Code
U01 Research Project – Cooperative Agreements
Announcement Type
Related Notices
Funding Opportunity Announcement (FOA) Number
Companion Funding Opportunity
RFA-HL-14-014, U01 Research Project – Cooperative Agreements
Catalog of Federal Domestic Assistance (CFDA) Number(s)
Funding Opportunity Purpose
This funding opportunity announcement (FOA) is for a Clinical Coordinating Center (CCC) for a new National Heart, Lung, and Blood Institute (NHLBI) Clinical Trials Network for the Prevention and Early Treatment of Acute Lung Injury (ALI) (PETAL Network). The Network will consist of approximately 11 Clinical Centers and 1 CCC. The Network will develop and conduct randomized controlled clinical trials to prevent, treat, and/or improve the outcome of adult patients with, or at risk, for ALI or the Acute Respiratory Distress Syndrome (ARDS). This FOA solicits applications for a CCC and runs parallel with a separate FOA for the CCs (RFA-HL-14-014). These awards are expected to be for 7 years.
Posted Date
May 15, 2013
Open Date (Earliest Submission Date)
June 25, 2013
Letter of Intent Due Date(s)
June 25, 2013
Application Due Date(s)
July 25, 2013, by 5:00 PM local time of applicant organization.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
AIDS Application Due Date(s)
Not Applicable
Scientific Merit Review
October-November 2013
Advisory Council Review
January 2014
Earliest Start Date
April 2014
Expiration Date
July 26, 2013
Due Dates for E.O. 12372
Not Applicable
Required Application Instructions
It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.
Part 1. Overview Information
Part 2. Full Text of the Announcement
Section I. Funding Opportunity Description
Section II. Award Information
Section III. Eligibility Information
Section IV. Application and Submission Information
Section V. Application Review Information
Section VI. Award Administration Information
Section VII. Agency Contacts
Section VIII. Other Information
The NHLBI Clinical Trials Network for the Prevention and Early Treatment of Acute Lung Injury (PETAL) will conduct randomized controlled clinical trials to prevent, treat, and/or improve the outcome of patients with, or at risk for, Acute Lung Injury (ALI) or the Acute Respiratory Distress Syndrome (ARDS). PETAL will consist of 1 Clinical Coordinating Center (CCC) solicited under RFA-HL-14-015 and approximately 11 Clinical Centers (CCs) to be solicited under RFA-HL-14-014. These awards are expected to be for 7 years. More than 1 trial will be conducted simultaneously, and it is expected that a minimum of 3-5 trials will be completed during the course of the award. The CCC will be responsible for coordinating all aspects of the Network.
This FOA builds on the demonstrated strengths and experience of the NHLBI Acute Respiratory Distress Syndrome Clinical Trial Network (ARDSnet), but shifts the focus towards prevention, earlier intervention, multidisciplinary collaborations, and new partnerships and approaches.
The goal of this new initiative will be very different from the current ARDSnet. Numerous observational studies suggest that ALI and ARDS can be prevented and outcomes improved in patients at risk of, but without, established disease. Recommendations from the critical care community stress the use of multidisciplinary approaches and studies of pre-ICU factors that will permit early identification and intervention in the emergency department (ED) or other locations within the hospital. This new initiative will require a collaborative team approach that will bring together pulmonary/critical care investigators, with experts in other relevant specialties including, but not limited to, emergency, trauma, sepsis, and infectious disease medicine or other that will ensure early access to eligible patients.
The scope of the Network studies will include patients at risk for ALI/ARDS including patients with shock or respiratory failure from sepsis as well as patients with established ALI/ARDS. Although the focus will be on early treatment and/or prevention, high-priority studies of novel treatments for established ALI and ARDS in ICU patients will be within the scope of this program. There will be latitude to propose and conduct clinical protocols that answer other significant questions that affect ALI/ARDS patients. Study endpoints are expected to be mortality, but other longer-term endpoints may be considered, as long as they are shown to have relevance to heart, lung, and blood disorders. Purely mechanistic studies are not appropriate for this Network.
Protocols will be selected and written by the Steering Committee (SC), which will be composed of the Intensive Care Unit clinician-investigator and a second investigator from a different specialty (e.g., emergency medicine, surgery, anesthesia) from each of the 11 CCs, as well as the CCC and NHLBI. The Network will be expected to consider protocol ideas from the wider critical care community from workshops and input from a PETAL public website. Protocols will be reviewed for scientific merit, validity, and feasibility by an independent NHLBI Protocol Review Committee (PRC). An independent NHLBI Data and Safety Monitoring Board (DSMB) will conduct interim reviews of trial data for patient safety and overall progress.
The Network will plan for and collect high-quality biospecimens that will permit the longitudinal molecular analysis of disease pathogenesis and recovery, as well as disease stratification in critically ill patients. These samples will be available to the wider research community for mechanistic work conducted under other funding mechanisms. Samples will be stored at a central laboratory repository at the CCC or at a subcontractor to the CCC and transferred to the NHLBI biorepository at the end of each trial.
The Network is expected to develop and participate in a cooperative, central, or shared IRB that will streamline IRB approval while maintaining patient safety.
In year 1, the PETAL Network is expected to be devoted to establishment of Network structure and procedures (including a cooperative IRB model), and selection and design of at least two clinical trial protocols. Years 2-7 will include protocol conduct, additional protocol designing, and routine Network functions. The last half of year 7 should be dedicated to Network closeout.
The CCC will be responsible for coordinating all aspects of PETAL. The CCC is expected to be experienced and highly competent in the coordination of complex clinical trials. The CCC will have a key role in trial design and analysis, and be responsible for oversight and monitoring, data collection, data integrity, reporting, training, and all PETAL Network operations. In addition to the usual varied responsibilities associated with organizing and overseeing a clinical trials Network, the CCC in cooperation with the NHLBI will (1) organize conferences in Year 1 and Year 5 with the broader critical care community to discuss priorities for prevention or early treatment clinical trials and developing a method to routinely welcome ideas for trials from the critical care community; (2) oversee development and storage of a biospecimen collection for molecular phenotyping of patients from samples collected by CCs at a central laboratory and transfer to the NHLBI biorepository in accordance with their guidelines at the end of trials; and (3) oversee development of an efficient, streamlined IRB review process which could be a collaborative, central, or shared IRB or some other method that will increase efficiency of trial reviews while maintaining safety and quality.
There are several new strategies that might prove beneficial in reducing the burden of ALI. This Network is expected to emphasize prevention and early treatment. New Food and Drug Administration (FDA) guidelines for testing combination therapies in serious illnesses open new possibilities. There may be novel treatment opportunities emerging through increasing understanding of the lung microbiome and the role of the host response in initiating, maintaining, and resolving lung injury. ALI/ARDS has several etiologies, and it is unknown whether different patients at risk (for example patients with sepsis, pneumonia, aspiration, or trauma) develop the same degree or type of lung injury, or whether treatments can be tailored and targeted to individual patients to either alleviate or prevent ALI/ARDS from developing. Initial studies of regenerative medicine approaches, such as using stem cell therapies, may be ready for testing in larger studies by this Network. Ventilation and blood transfusion strategies or changes in antibiotic management may need to be applied to early intervention of acute lung injury. Although the focus of this program is on prevention and early treatment of ALI/ARDS, high-priority studies of novel strategies for treating established ALI and ARDS will be permissible. Studies that could optimize treatments for ALI/ARDS of different etiologies would be appropriate. There will be latitude to propose clinical protocols that address other significant questions that affect patients with ALI/ARDS that have the potential to substantially improve clinical outcomes. .
Funding Instrument
Cooperative Agreement: A support mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities.
Application Types Allowed
The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types.
Funds Available and Anticipated Number of Awards
The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications
It is estimated that approximately $53 million (Total Costs) will be awarded to the CCC over a 7-year period.
One CCC will be funded by this award.
Award Budget
Application budgets are limited to a maximum of $857,142 (Direct Costs) for the first year excluding patient care costs.
Budgets for years 2 through 7 are limited to a maximum of $1,123,809 (Direct Costs) related to core activities.
Budgets should also include patient care costs for $7,280,000 in each of years 2 through 6 and $3,300,000 in year 7.
Budgets need to reflect the actual needs of the proposed project.
Award Project Period
The total project period for an application submitted in response to this funding opportunity may not exceed 7 years.
NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made in response to this FOA.
Higher Education Institutions
The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:
Nonprofits Other Than Institutions of Higher Education
For-Profit Organizations
Non-domestic (non-U.S.) Entities (Foreign Institutions) are
not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Applicant Organizations
Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The NIH Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.
Program Directors/Principal Investigators (PD(s)/PI(s))
All PD(s)/PI(s) must have an eRA Commons account and should work with their organizational officials to either create a new account or to affiliate an existing account with the applicant organization's eRA Commons account. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.
Any individual(s) with the skills, knowledge, and resources
necessary to carry out the proposed research as the Program Director(s)/Principal
Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to
develop an application for support. Individuals from underrepresented racial
and ethnic groups as well as individuals with disabilities are always
encouraged to apply for NIH support.
For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.
The CCC will have two key investigators (PDs/PIs). The PDs/PIs must be a senior statistician with demonstrated experience in coordinating clinical trials, preferably in critically ill patients. The second key investigator will have demonstrated experience in clinical trials in critically ill patients, appropriately Board-certified and actively involved in the care and study of pulmonary and critically ill patients, especially those with ALI/ARDS.
This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.
Applicant organizations may submit more than one application, provided that each application is scientifically distinct.
NIH will not accept any application that is essentially the same as one already reviewed within the past thirty-seven months (as described in the NIH Grants Policy Statement), except for submission:
Proposals submitted in response to contract solicitation NHLBI-HR-14-03 do not violate the above prohibition on submission of essentially same applications within 37 months. NHLBI cancelled the contract solicitation and is instead issuing this cooperative agreement mechanism, thus proposals submitted to NHLBI-HR-14-03 will not be reviewed.
Applicants must download the SF424 (R&R) application package associated with this funding opportunity using the "Apply for Grant Electronically" button in this FOA or following the directions provided at Grants.gov.
It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
For information on Application Submission and Receipt, visit Frequently Asked Questions – Application Guide, Electronic Submission of Grant Applications.
Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.
By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:
The letter of intent should be sent to:
Director, Office of Scientific Review
National Heart, Lung, and Blood Institute
6701 Rockledge Drive
Room 7214, MSC 7924
Bethesda, MD 20892-7924 (Express zip: 20817)
Telephone: (301) 435-0270
Email: firstname.lastname@example.com
All page limitations described in the SF424 Application Guide and the Table of Page Limits must be followed.
The forms package associated with this FOA includes all applicable components, required and optional. Please note that some components marked optional in the application package are required for submission of applications for this FOA. Follow all instructions in the SF424 (R&R) Application Guide to ensure you complete all appropriate "optional" components.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:
The CCC will have two key investigators. The PD/PI will be a senior statistician with demonstrated experience in coordinating clinical trials. The second key investigator will have demonstrated experience in clinical trials in critically ill patients, appropriately Board-certified and actively involved in the care and study of pulmonary and critically ill patients, especially those with ALI/ARDS.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:
To justify the personnel component of the budget, in addition to the standard biosketches including the tailored individual statement for key personnel, the applicant should include a table outlining the expertise and effort proposed for the CCC. Effort should differ during Year 1 startup (protocol writing, Network operations, data base preparation) and Year 7 close down (finalizing data bases, final manuscripts, transferring data and biospecimens to NHLBI). Expertise typically needed for a CCC includes project management, nurse coordinator, biostatistics, computer expertise including data base creation and management, website development. For this FOA, expertise in biobanking is needed.
Suggested travel:
Year 1:
Years 2 through 7:
Other costs to be included but not limited to:
Biospecimen lab
A budget should be proposed to support a central biospecimen lab. This should include sufficient labor to establish procedures that meet quality standards of the NHLBI Biorepository (BioLINCC https://biolincc.nhlbi.nih.gov/home). Costs include sample collection kits assuming several types of biospecimens that would be useful for molecular phenotyping (e.g., inflammatory and other biomarkers, expression analysis, and tissue analysis), shipping containers and shipping costs for the CCs, costs for storage at the CC biorepository, and costs for final shipping to the NHLBI biorepository. Costs for Q/A should be described. This biospecimen collection plan will be finalized by the SC, but the CCC should present a vision and budget for the biospecimen collection.
A subcontract may be proposed for the biospecimen repository.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:
In lieu of a Research Strategy with the usual headings, the applicant should describe their experience and plans for carrying out the duties involved in overseeing a complex clinical trials network. Some of the duties are listed below.
This CCC will have four additional roles that should be addressed: (1) methods to routinely solicit/welcome research ideas from the wider critical care community (e.g., public website), (2) overseeing development of more efficient IRB process by the SC, and (3) development and operation of a biospecimen lab. This plan should outline a vision for the types of samples that would support molecular phenotyping appropriate for critically ill patients.
The Research strategy section may include any other information that the applicants deem important for determination of merit.
Letters of Support: Provide letters of support, including letter indicating institutional willingness to participate in cooperative, central, or shared IRB model developed by the SC, as a single PDF file with the name "PETAL support.pdf."
Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans (Data Sharing Plan, Sharing Model Organisms, and Genome Wide Association Studies (GWAS)) as provided in the SF424 (R&R) Application Guide.
Appendix: Do not use the Appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.
Part I. Overview Information contains information about Key Dates. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission.
Organizations must submit applications to Grants.gov, the online portal to find and apply for grants across all Federal agencies. Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH's electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date. If a Changed/Corrected application is submitted after the deadline, the application will be considered late.
Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.
Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.
This initiative is not subject to intergovernmental review.
All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Pre-award costs are allowable only as described in the NIH Grants Policy Statement.
Funds budgeted for protocol capitations and SC chair effort will be restricted for these purposes.
Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide. Paper applications will not be accepted.
Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.
For assistance with your electronic application or for more information on the electronic submission process, visit Applying Electronically.
All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile Component of the SF424(R&R) Application Package. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this FOA for information on registration requirements.
The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization's profile in the eRA Commons and for the System for Award Management. Additional information may be found in the SF424 (R&R) Application Guide.
See more tips for avoiding common errors.
Upon receipt, applications will be evaluated for completeness by the Center for Scientific Review and responsiveness by NHLBI, NIH. Applications that are incomplete and/or nonresponsive will not be reviewed.
Applicants are required to follow the instructions for post-submission materials, as described in NOT-OD-10-115.
Only the review criteria described below will be considered in the review process. As part of the NIH mission, all applications submitted to the NIH in support of biomedical and behavioral research are evaluated for scientific and technical merit through the NIH peer review system.
Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).
Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.
Does the project address an important problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?
Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or New Investigators, or in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?
Is the PD/PI a senior statistician with experience managing complex clinical trials, especially ALI/ARDS?
Is the PD/PI knowledgeable about clinical trial design and analysis?
Does the staff of the CCC have experience and qualifications in clinical trial management?
Is the Critical Care key investigator (one of the PDs/PIs) experienced in working with clinical trials in critically ill patients?
Is there an investigator associated with the proposed biospecimen lab who is knowledgeable about biomarkers and biospecimens?
Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?
Have innovative, cost-effective approaches to clinical trial design, data collection, training, CC oversight and information sharing been described?
Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed?
Are economical and efficient means for communication with and among CCs described?
Is there a good plan for obtaining clinical trial ideas from the wider critical care community?
Is the plan for the biospecimen repository sufficient
to result in high quality specimens?
If the project involves clinical research, are the plans for 1) protection of human subjects from research risks, and 2) inclusion of minorities and members of both sexes/genders, as well as the inclusion of children, justified in terms of the scientific goals and research strategy proposed?
Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?
Has the Institution indicated a willingness to participate in a cooperative, central, or shared IRB?
Are facilities available for secure data and biospecimen storage?
As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.
Protections for Human Subjects
For research that involves human subjects but does
not involve one of the six categories of research that are exempt under 45 CFR
Part 46, the committee will evaluate the justification for involvement of human
subjects and the proposed protections from research risk relating to their
participation according to the following five review criteria: 1) risk to
subjects, 2) adequacy of protection against risks, 3) potential benefits to the
subjects and others, 4) importance of the knowledge to be gained, and 5) data
and safety monitoring for clinical trials.
For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Human Subjects Protection and Inclusion Guidelines.
Inclusion of Women, Minorities, and Children
When the proposed project involves clinical research, the committee will evaluate the proposed plans for inclusion of minorities and members of both genders, as well as the inclusion of children. For additional information on review of the Inclusion section, please refer to the Human Subjects Protection and Inclusion Guidelines.
Vertebrate Animals
The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following five points: 1) proposed use of the animals, and species, strains, ages, sex, and numbers to be used; 2) justifications for the use of animals and for the appropriateness of the species and numbers proposed; 3) adequacy of veterinary care; 4) procedures for limiting discomfort, distress, pain and injury to that which is unavoidable in the conduct of scientifically sound research including the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices; and 5) methods of euthanasia and reason for selection if not consistent with the AVMA Guidelines on Euthanasia. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.
Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.
Not Applicable
Not Applicable
Not Applicable
As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.
Applications from Foreign Organizations
Not Applicable
Select Agent Research
Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).
Resource Sharing Plans
Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: 1) Data Sharing Plan; 2) Sharing Model Organisms; and 3) Genome Wide Association Studies (GWAS).
Budget and Period of Support
Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.
Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by the NHLBI in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.
As part of the scientific peer review, all applications:
Appeals of initial peer review will not be accepted for applications submitted in response to this FOA.
Applications will be assigned to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications submitted in response to this FOA. Following initial peer review, recommended applications will receive a second level of review by the NHLBI Advisory Council. The following will be considered in making funding decisions:
After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons.
Information regarding the disposition of applications is available in the NIH Grants Policy Statement.
If the application is under consideration for funding, NIH
will request "just-in-time" information from the applicant as
described in the NIH
Grants Policy Statement.
A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the grantee's business official.
Awardees must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.
Any application awarded in response to this FOA will be subject to the DUNS, SAM Registration, and Transparency Act requirements as noted on the Award Conditions and Information for NIH Grants website.
All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities. More information is provided at Award Conditions and Information for NIH Grants.
Cooperative Agreement Terms and Conditions of Award
The following special terms of award are in addition to, and
not in lieu of, otherwise applicable U.S. Office of Management and Budget (OMB)
administrative guidelines, U.S. Department of Health and Human Services (DHHS)
grant administration regulations at 45 CFR Parts 74 and 92 (Part 92 is
applicable when State and local Governments are eligible to apply), and other
HHS, PHS, and NIH grant administration policies.
The administrative and funding instrument used for this program will be the cooperative agreement, an "assistance" mechanism (rather than an "acquisition" mechanism), in which substantial NIH programmatic involvement with the awardees is anticipated during the performance of the activities. Under the cooperative agreement, the NIH purpose is to support and stimulate the recipients' activities by involvement in and otherwise working jointly with the award recipients in a partnership role; it is not to assume direction, prime responsibility, or a dominant role in the activities. Consistent with this concept, the dominant role and prime responsibility resides with the awardees for the project as a whole, although specific tasks and activities may be shared among the awardees and the NIH as defined below.
The PD(s)/PI(s) will have the primary responsibility for:
The Clinical Coordinating Center PD/PI will be responsible
for the overall function of all PETAL research activities. The CCC PD/PI
will be responsible for oversight of protocol development, drug acquisition and
distribution, data collection, data safety and confidentiality, quality
assurance, data analysis, coordination of data distribution, and implementation
of all data sharing plans. The CCC PD/PI will be responsible for the
distribution of protocol funds to the Clinical Centers (see "Funds Available"
in Section II. 2. RFA-HL-14-014).
The CCC PD/PI will be responsible for coordination of manuscript preparation,
activities of the Steering Committee, Protocol Review Committee, and Data and Safety
Monitoring Board.
Support or other involvement of industry or any other third party in the PETAL studies may be advantageous and appropriate. Awardees must follow NHLBI policy concerning third party agreements.
Awardees will retain custody of and have primary rights to the data and software developed under these awards, subject to Government rights of access consistent with current HHS, PHS, and NIH policies.
NIH staff have substantial programmatic involvement that is above and beyond the normal stewardship role in awards, as described below:
The PETAL program scientist (PS) will participate in Steering Committee activities. Several procedures are in place to manage potential conflicts of interest by PS administering the cooperative agreement. PS adhere to stringent NIH ethics rules and financial disclosure; staff are prohibited from observing scientific review of competing applications from an investigator with whom they have published in the last three years; recommendations from PS about budgetary requests (e.g., carryover, administrative supplements, no-cost extensions) are reviewed and approved by supervisors (e.g., Branch Chiefs, Division Director, and, Institute Director); recruitment progress is reviewed by study independent staff (quarterly within the Division; semi-annually or quarterly by the DSMB and supervisory staff, and annually by the NHLBI Director; PS will generally be asked to leave the room during DSMB reviews of study results; recommendations made by PS in annual progress reports are reviewed by grant specialists in a separate Division (Office of Grants Management); PS will not seek lead authorship of primary publications and will obtain approval by Branch Chief to participate in secondary publications.
Program staff may work with awardees on issues coming before
the Steering Committee and, as appropriate, other committees (e.g.,
recruitment, intervention, follow-up, quality control, adherence to protocol,
assessment of problems affecting the study and potential changes in the
protocol, interim data and safety monitoring, final data analysis and
interpretation, and preparation of publications). NHLBI Program staff, on
behalf of the NHLBI, will have the same access, privileges, and
responsibilities regarding the collaborative data as the other members of the
Steering Committee.
The NHLBI reserves the right to phase out a PETAL study (or an individual award) in the event of (1) failure to develop or implement mutually agreeable collaborative protocol; (2) substantial shortfall in participant recruitment, follow-up, data reporting, or quality control; (3) major breach of a protocol or substantive changes in the agreed-upon protocol with which NHLBI cannot concur; (4) attaining of a major study endpoint before schedule with persuasive statistical significance; or (5) human subject ethical issues that may dictate an early phase out of a trial or the program.
Annual continuation and level of funding for the CCC will be based on NHLBI review of actual recruitment and overall performance, determined as part of the NHLBI review of the annual non-competing continuation grant progress reports submitted by awardees.
Additionally, an agency program official or IC program director will be responsible for the normal scientific and programmatic stewardship of the award and will be named in the award notice.
Areas of Joint Responsibility include:
Awardees agree to the governance of the study through a
Steering Committee (SC). Two investigators from each CC and the CCC, a
Chairperson, to be appointed by the NHLBI, and an NHLBI representative will
comprise the SC. All major scientific decisions will be determined by
majority vote of the SC. Each Clinical Center, the Clinical Coordinating
Center, and the NHLBI Program Office will have one vote; the Chair will have
one vote in case of a tie. Note that although each Clinical Center is
expected to have two representative participants (one with expertise in critical
care, one with expertise in emergency medicine or some other specialty with
early access to patients) in all SC meetings, each Clinical Center has only one
vote. It is anticipated that SC meetings will be held at least once a
month by conference call and two times a year in person. The first year during
Network establishment and initial protocol selection, may require more frequent
An independent Protocol Review Committee (PRC) will provide peer review for each PETAL protocol. The PRC will be appointed by and be advisory to the NHLBI. It will consist of a chairperson, and Executive Secretary who is an NHLBI scientist other than the NHLBI Project Scientist, and scientists with expertise in clinical trial design, biostatistics and clinical coordinating center management, asthma clinical management and research in adults and pediatrics, bioethics, and other areas of expertise as needed. Because the Board serves as an independent group advisory to the NHLBI, study investigators will not communicate with Board members regarding study issues, except as authorized by PRC Executive Secretary. The PRC will evaluate protocols proposed by the SC based on the significance of the questions to be addressed, scientific merit and innovation of the experimental design and approach, feasibility, appropriateness for the Network and consistency with NHLBI missions and policies. The PRC will provide a written critique of each proposal and a final recommendation to the NHLBI. All study protocols performed by PETAL will be recommended by the PRC and approved by the NHLBI before initiation.
An independent Data and Safety Monitoring Board (DSMB) will be appointed by the Director, NHLBI to provide overall monitoring of study performance, interim data, and safety issues. An NHLBI scientist, other than the NHLBI Program Scientists, shall serve as Executive Secretary to the DSMB.
Awardee members of the Steering Committee will be required to accept and implement policies approved by the Steering Committee.
Dispute Resolution:
Any disagreements that may arise in scientific or programmatic matters (within the scope of the award) between award recipients and the NIH may be brought to Dispute Resolution. A Dispute Resolution Panel composed of three members will be convened. It will have three members: a designee of the Steering Committee chosen without NIH staff voting, one NIH designee, and a third designee with expertise in the relevant area who is chosen by the other two; in the case of individual disagreement, the first member may be chosen by the individual awardee. This special dispute resolution procedure does not alter the awardee's right to appeal an adverse action that is otherwise appealable in accordance with PHS regulation 42 CFR Part 50, Subpart D and DHHS regulation 45 CFR Part 16.
Funds budgeted for capitation reimbursement to CC and salary for SC chair will be restricted for these purposes.
When multiple years are involved, awardees will be required to submit the annual Non-Competing Progress Report (PHS 2590 or RPPR) and financial statements as required in the NIH Grants Policy Statement.
A final progress report, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement.
The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000. See the NIH Grants Policy Statement for additional information on this reporting requirement.
We encourage inquiries concerning this funding opportunity
and welcome the opportunity to answer questions from potential applicants.
eRA Commons Help Desk (Questions regarding eRA Commons
registration, submitting and tracking an application, documenting system
problems that threaten submission by the due date, post submission issues)
Phone: 301-402-7469 or 866-504-9552 (Toll Free)
Web ticketing system: https://public.era.nih.gov/commonshelp
Email: firstname.lastname@example.com
Customer Support (Questions
regarding Grants.gov registration and submission, downloading forms and
application packages)
Contact Center Phone: 800-518-4726
Email: firstname.lastname@example.com
GrantsInfo (Questions regarding application instructions and
process, finding NIH grant resources)
Telephone 301-710-0267
Email: firstname.lastname@example.com
Andrea L. Harabin, Ph.D.
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0222
Email: firstname.lastname@example.com
Director, Office of Scientific Review
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0270
Email: email@example.com
Gayle Jones
National Heart, Lung and Blood Institute (NHLBI)
Telephone: 301-435-0140
Email: email@example.com
Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Parts 74 and 92.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
Department of Health
and Human Services (HHS)
NIH... Turning Discovery Into Health®
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.


text:
Sponsored by Career Center
Bring your laptop and roll up your sleeves as we will begin searching for internships! Our goal is for each student to have ten leads by the time they finish the workshop.
Topics include: Registration and paperwork involved in an internship, paid vs. unpaid internships, ways to search for an internship, how to get the most out of your internship, and funding for your Summer internship.
Questions? Contact Dan Marlow, 563-387-1472

subset: commoncrawl


text:
Follow us on
Brand new stock
Our Price
Print Details
Enter your registration number and mileage for an instant online valuation
Barker St,
Tel: 01603 623800
How to Find Us
Is this vehicle not quite right? Here are some similar vehicles that you may be interested in..
Search Used
The cookie settings on this website are set to "allow all cookies". This is so that we can give you the very best experience while you're on our website. You can adjust your cookie settings at any time in your browser preferences. Find out more
If you would like to be contacted in the future about this or similar vehicles then please provide your consent to the following contact methods.


text:
This policy (together with our Terms and Conditions, full Data Protection Policy and any other documents referred to in it) sets out the basis on which any personal data we collect from you, or that you provide to us, will be processed by us. Please read the following carefully to understand our views and practices regarding your personal data and how we will treat it.
Use of this website by you constitutes acceptance by you of this privacy policy ("Privacy Policy"). If you do not wish to accept this Privacy Policy, please leave this website immediately.
The purpose of this Privacy Policy is:
This Privacy Policy governs this website at www.flelearning.co.uk (referred to in this Privacy Policy as the "Website") and other affiliated websites of FLE Learning.
This Privacy Policy covers only information which is collected by FLE Learning from the Website.
Data protection
FLE Learning complies with the Data Protection Act 1998 (the "Act"). For the purposes of the Act, FLE Learning is the data controller and sole owner of the personal data collected on the Website.
FLE Learning does not sell, share or transfer this information except as set out in this Privacy Policy.
We use up-to-date industry procedures to keep personal data as safe and secure as possible and to protect against loss, unauthorised disclosure or access. Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to the Website; any transmission is at your own risk. Once we have received your information, we will use strict procedures and security features to try to prevent unauthorised access.
The Act gives you the right to access details that we hold about you. Your right of access can be exercised in accordance with the Act. A small fee may be payable in respect of any access request. For more detailed information, please refer to our full Data Protection Policy.
Information Collected and Stored Automatically
When visiting our web pages, tracking technologies may record information about your visit automatically. This information does not identify you personally. We automatically collect and store only the following information about your visit.
We use this information to help us identify click stream patterns, to improve our website and to learn about the number of visitors to our website and the types of technology our visitors use. We only use this information to ensure that our web pages stay compatible with a cross selection of browsers and systems and thereby ensure that the pages appeals to a wider audience. We do not track or record information about individuals and their visits.
Information we may collect from you
If you are a delegate (and/or a potential delegate) on one of our training courses or conferences, we will collect from you and process only those data that are necessary for the administration of the event or conference, which will include the following basic personal information about you:
Uses made of the information
We may use information held about you in the following ways:
We may also use your data for the purposes of advertising, marketing and public relations, so as to provide you with information about our services and events which may be of interest to you. If you do not want us to use your data in this way or no longer wish to receive such information, please email firstname.lastname@example.com
Please see our separate page on Cookies.
Changing the information we hold about you
If you would like to change any information we hold about you that has been collected via use of this Website or want to it to be removed from our database, you should contact us at email@example.com
Third Parties
FLE Learning discloses potentially personally-identifying and personally-identifying information only to those of its employees, contractors and affiliated organisations that (i) need to know that information in order to process it on FLE Learning's behalf or to provide services available at FLE Learning's websites, and (ii) that have agreed not to disclose it to others. Some of those employees, and affiliated organisations may be located outside of your home country; by using FLE Learning's websites, you consent to the transfer of such information to them. FLE Learning will not rent or sell potentially personally-identifying and personally-identifying information to anyone. Other than to its employees, contractors and affiliated organisations, as described above, FLE Learning discloses potentially personally-identifying and personally-identifying information only when required to do so by law, or when FLE Learning believes in good faith that disclosure is reasonably necessary to protect the property or rights of FLE Learning, third parties or the public at large. FLE Learning takes all measures reasonably necessary to protect against the unauthorised access, use, alteration or destruction of potentially personally-identifying and personally-identifying information. For more detailed information, please see our separate page on 'Data Protection Policy'.
By using the Website, you consent to the collection and use of your personal information in the manner set out above.
You have the right to ask us not to process your personal data for marketing purposes. You can exercise your right to prevent such processing at any time by contacting us at email@example.com.
The internet and data privacy best practice are both developing. We therefore reserve the right to revise this Privacy Policy at any time. If this Privacy Policy changes in any way, we will place an updated version on this page. Regularly reviewing this page ensures you are always aware of what information we collect, how we use it and under what circumstances, if any, we will share it with other parties.
Questions, comments and requests regarding this Privacy Policy are welcomed and should be addressed to firstname.lastname@example.com.


text:
WASHINGTON – Federal health officials say Agent Orange and other herbicides that were sprayed at a Canadian military base posed no health risks to the thousands of National Guard members from Maine and other states who trained there for decades.
But the findings by the U.S. Centers for Disease Control and Prevention are unlikely to satisfy veterans who believe their health problems are linked to the weeks they spent in the dirt at Canadian Forces Base Gagetown in New Brunswick. And U.S. Sen. Susan Collins, R-Maine, expressed disappointment at the scope of the review.
"While I appreciate that the CDC shares my concerns about the health of our service members and veterans who trained at Gagetown, I am disappointed that it does not appear that the thorough investigation the administration promised to undertake went beyond a review of the pre-existing Canadian report," Collins said Tuesday.
In June, Collins asked the CDC's Agency for Toxic Substances and Disease Registry to review a 2007 Canadian study of health risks from herbicides used at Gagetown and advise her office on levels of chemicals that were sprayed at the base. The CDC expressed no qualms with the Canadian report's findings.
"We concluded that concentrations of contaminants at CFB Gagetown did not represent a public health hazard to members of the U.S. military or National Guard," CDC Director Thomas Frieden wrote to Collins on March 1 in a letter accompanying the report. "While exposures may have occurred during training at CFB, the levels of herbicide were below levels of concern for both cancerous and non-cancerous health effects."
The Gagetown training base, southeast of Fredericton, was used by thousands of National Guard members from Maine, Massachusetts, New Hampshire and other states from 1971 to 2006. Units often spent two weeks training at the base, with more than 250,000 acres, 700-plus buildings and 1,500 miles of roads. More than 300,000 Canadian military personnel served or trained at Gagetown as well.
Veterans on both sides of the border -- including more than 100 in Maine -- have been struggling for years to qualify for disability benefits for ailments they blame on the use of herbicides and defoliants at Gagetown.
At the top of the list of chemicals is Agent Orange, a defoliant that was widely used during the Vietnam War and has been linked to cancer, Hodgkin's disease, birth defects and other diseases. Canadian officials also sprayed large quantities of other herbicides and defoliants at Gagetown over the decades.
Veterans administration officials in the U.S. and Canada have rejected almost all claims except those filed by service members who served at Gagetown in 1966 and 1967, when the U.S. military tested Agent Orange there.
But many of the veterans whose claims were denied believe that the other chemicals -- including close relatives to Agent Orange -- may be causing their health problems.
The CDC did not do its own investigation of conditions at Gagetown. Instead, it reviewed the Canadian government's 2007 report on herbicide use from 1952 to 2004 at Gagetown. It agreed with the original report's conclusions after determining that the soil sampling methods, tests and risk assessment standards were the same as the CDC would have used.
"There is little to no increased risk of adverse effects on blood-forming tissues, the liver, and the central nervous system, and the risk of skin disorders or developmental effects is not enough to represent a public health hazard," says the report.
Collins suggested Tuesday that she had expected the CDC to probe deeper. Her request specifically asked the agency to review the 2007 report, and posed a series of questions about the amounts and concentration of herbicides used and the safety precautions.
"I would have hoped that the CDC would have sought to interview medical providers treating those who were possibly exposed to harmful chemicals and became ill," Collins said in a prepared statement. "It is unclear from the letter I received, or the report itself, whether those investigative steps were taken."
Richard Pelletier, a veteran who has been one of the most forceful advocates on the Gagetown issue, said Collins "should have known better" than to ask a U.S. government office to look into the matter. Like many affected veterans on both sides of the border, Pelletier says that the U.S. and Canadian governments are covering up the issue to limit liability.
He said an independent panel needs to investigate.
"It doesn't surprise me it is the same decision. It is going to be the same decision" absent an independent review, Pelletier said Tuesday night. "We didn't get any farther. It's six or seven months later and we still have the same story."
A spokeswoman for the U.S. Department of Veterans Affairs said Tuesday that the department was still reviewing the report and was unable to comment.


text:
Live the Made to Order experience in dedicated rooms in select Fendi Boutiques worldwide.
Handmade Bags - Bespoke Goods | Fendi

Get the perfect item with Fendi's Made to Order service and receive a personalized, bespoke product with an endless array of possibilities. Find out more today.

Handmade Bags - Bespoke Goods | Fendi


text:
RN - Registered Nurse
Cherokee, IA
Job Description
Join the Aventure team of caring healthcare professionals as a RN (Registered Nurse).
Pay starts at $26/hr & can increase depending on experience.
At Aventure, RN (Registered Nurse)'s will find:
- Choice of shifts that best fit your schedule!*
- Team-centered atmosphere & positive interactions with thoughtful, friendly scheduling staff
- Weekly pay (Fridays) & Direct Deposit
- Paid Time Off & Holiday Pay**
Choose from a variety of facilities throughout NW Iowa, SE South Dakota & NE Nebraska!
Requirements of a RN (Registered Nurse):
- Valid RN License
- Current CPR/BCLS Certificate
- Current TB Test & Physical
- Mandatory Reporter Certificate is preferred, but we can help obtain!
Come experience the Aventure difference! Call Rhyen at (712) 224-4810 for more information!
*Typical shift times include: 6a-2p, 2p-10p, 10p-6a - Shift times may vary by location
**Holiday Pay = 1 ½ times base pay if you work the actual holiday
EOE/AA – Drug and/or background check may be required


text:
Compressed Sensing Cardiac Cine
Beyond speed. Beyond breath-holds.
MRI provides great diagnostic imaging value. However, in some cases it's still too slow for imaging arrhythmic and dyspneic patients.
As the first clinical application based on our disruptive speed technology, Compressed Sensing Cardiac Cine changes the game. Rather than taking nearly six minutes, a Cardiac Cine scan can now be done within 25 seconds1 – in free-breathing.
The first clinical application based on Compressed Sensing helps you to:
- Acquire free-breathing, high-resolution Cardiac Cine images
- Capture the whole cardiac cycle for precise quantification
- Expand patient population eligible for cardiac MRI
Customer experience with Compressed Sensing Cardiac Cine:
At RSNA 2016 we've introduced Compressed Sensing Cardiac Cine, which is designed to acquire free-breathing, high-resolution Cardiac Cine images and therefore, expanding patient population eligible for cardiac MRI. Dr. François Ascagne Pontana from the CHU de Lille, Lille, France is one of first users – listen to his experiences.
General Requirements
Minimum Software Version
syngo MR E11C
Also available for:
MAGNETOM Avantofit
MAGNETOM Prismafit
Please note: Additional technical prerequisites may apply. Upon receiving your request, your local Siemens representative will clarify whether your system meets the requirements.
Related Products, Services & Resources
1Sudarski et. al., Radiology. 2016 Jul 11:151002.


text:
VCA Asher Animal Hospital, one of VCA'™s premier 24-hour practices, is seeking an Associate Veterinarian to join our team in gorgeous Redding, California. We are excited to mentor a new graduate and can offer excellent experience in general practice and emergency medicine for the motivated candidate. The successful candidate will be a personable, happy, charismatic individual with strong interpersonal skills who enjoys a family atmosphere at work.
In this position you will be supported 24/7 by a well-trained, friendly group of veterinary professionals - allowing you to focus on providing excellent medical care to your patients. Along the way you'™ll build a loyal client base and we'™ll help you continually grow through continuing education. As a General Practitioner with VCA, you'™ll have access to our brain trust of board certified Specialists, among the many resources of North America'™s leader in veterinary medicine.
The hospital itself is located in one of the most beautiful parts of the country. Nestled within the Sierra's, you will enjoy a low-key lifestyle with a desirable cost of living, and no traffic to get in your way on the drive to enjoy the beautiful lakes, hiking, fishing, and other numerous outdoor activities. For anyone with an interest in the outdoors, Redding should be seriously considered.
More info about Redding, CA: www.facebook.com/100008276921661/videos/2121406638145213/
As a member of the VCA family, your passion for medicine and compassion for pets and people is matched with a commitment to your professional growth. Among the reasons to consider joining VCA are: '¢ Network of 4,500+ doctors, including more than 600 Specialists.'¢ Largest provider of Private Practice Internships and Residencies in the U.S.'¢ WOOF University, offering abundant CE for Doctors and Staff.'¢ Robust Clinical Studies program.'¢ Opportunities to give back through strong Shelter partnerships and VCA Charities. We offer competitive compensation and great benefits for eligible employees, including medical/dental, generous personal pet care discounts and more!
2144 Commons Parkway
Okemos, MI 48864-3986


text:
Enter keywords to search above or go directly to a search below.
We carry parts for .
Take a look at our selection of thoroughly inspected trucks and find a truck that meets your needs.
We buy used trucks and equipment, including all types of diesel engines and transmissions, running or not.
Find an LKQ store near you. You can click here to find where to go and who to call.


text:
OKLAHOMA CITY — It's a warning as familiar as a daily prayer for Tornado Alley residents: When a twister approaches, take shelter in a basement or low-level interior room or closet, away from windows and exterior walls.
But with the powerful devastation from the May 20 twister that killed 24 and pummeled the Oklahoma City suburb of Moore still etched in their minds, many Oklahomans instead opted to flee Friday night when a violent tornado developed and headed toward the state's capital city.
It was a dangerous decision to make.
Interstates and roadways already packed with rush-hour traffic became parking lots as people tried to escape the storm. Motorists were trapped in their vehicles — a place emergency officials say is one of the worst to be in a tornado.
"It was chaos. People were going southbound in the northbound lanes. Everybody was running for their lives," said Terri Black, 51, a teacher's assistant in Moore.
After seeing last month's tornado also turn homes into piles of splintered rubble, Black said she decided to try to outrun the tornado when she learned her southwest Oklahoma City home was in harm's way. She quickly regretted it.
When she realized she was a sitting duck in bumper-to-bumper traffic, Black turned around and found herself directly in the path of the most violent part of the storm.
"My car was actually lifted off the road and then set back down," Black said. "The trees were leaning literally to the ground. The rain was coming down horizontally in front of my car. Big blue trash cans were being tossed around like a piece of paper in the wind. I'll never do it again."
Oklahoma Highway Patrol Trooper Betsy Randolph said the roadways were congested with the convergence of rush-hour traffic and fleeing residents.
"They had no place to go, and that's always a bad thing. They were essentially targets just waiting for a tornado to touch down," Randolph said. "I'm not sure why people do that sort of stuff, but it is very dangerous. It not only puts them in harm's way, but it adds to the congestion. It really is a bad idea for folks to do."
At least nine people were killed in Friday's storms, including a mother and her baby sucked out of their car as a deadly twister tore its way along a packed Interstate 40 near the town of El Reno, about 30 miles from Oklahoma City.
"We believe all the victims were in vehicles when the storm came through," Canadian County Undersheriff Chris West said Saturday.
More than 100 people were injured, most of those from punctures and lacerations from swirling debris, emergency officials reported.
Oklahoma wasn't the only state to see violent weather Friday night. In Missouri, areas west of St. Louis received significant damage from an EF3 tornado that packed estimated winds of 150 mph. In St. Charles County, at least 71 homes were heavily damaged and 100 had slight to moderate damage, said county spokeswoman Colene McEntee.
Tens of thousands were without power, and eight minor injuries were reported. Gov. Jay Nixon declared a state of emergency.
Northeast of St. Louis and across the Mississippi, the city of Roxana was hit by an EF3 tornado as well, but National Weather Service meteorologist Jayson Gosselin said it wasn't clear whether the damage in both states came from the same EF3 twister or separate ones.
Back in Oklahoma, Amy Williamson, who lives just off I-40 in the western Oklahoma City suburb of Yukon, said when she learned the tornado was moving toward her home, she piled her two children, babysitter and two cats into her SUV.
"We felt like getting out of the way was the best idea," Williamson said. "It was 15 minutes away from my house, and they were saying it was coming right down I-40, so we got in the car and decided to head south."
Williamson said she knows emergency officials recommend taking shelter inside a structure, but fresh in her mind was the devastation of the Moore tornado. Seeing homes stripped to their foundation made her think that fleeing was the best idea, she said. She ended up riding out the storm in a hospital parking garage.
On Saturday, floodwaters stood several feet deep in the countryside surrounding the metro area. Torrential downpours followed for hours after the twisters moved east — up to 7 inches of rain in some parts — and the city's airport had water damage. Some flights resumed Saturday.
The Oklahoma County Sheriff's Office said a man was missing from a vehicle near Harrah, east of Oklahoma City. Roadways around the area were crumbling because of water, especially near an intersection in northeastern Oklahoma City and in Canadian County south of I-40, between Mustang and Yukon.


text:
Adelaide designers come under fire by disability advocates after launching their 'Retarde' clothing line
Two Adelaide designers have come under fire for a clothing line which has been described as discriminatory and humiliating.
Disability advocates are furious after t-shirts and jumpers with the word "Retarde" on the front were released by the Art of Aztec label created by fashion designers Renae Beaty and Ema Raw.
Angry protesters gathered outside the youth retail chain Globalize store in Adelaide's Rundle Mall, which began stocking the newly released label last week.
Protester Karen Haupteman, whose intellectually disabled son died when he was nine, says it is her job to speak for him and the many others who are unable to stand up for themselves.
"The word retard, or retarde, only means one thing. It's a word that's used to bully. Kids are killing themselves, kids are committing suicide because they're being bullied," she said.
"These kids are marginalised, they're non verbal. We're their mothers. We're here to speak for them. We're here to let people know it's not ok.
"Hate, discrimination, humiliation, it's not on."
Protesters waved placards which read "hate speech is unacceptable" and "ditch the R word today" outside the Globalize clothing store in Rundle Mall.
One protester, Sam, says life is hard enough for her 13-year-old son and says this kind of abuse is like a kick in the guts.
"The day that my kid came home from school and said that he'd been called a retard, it was actually one of the most devastating days of my life," she said.
"I know that sounds weak, but I think it just brought home the nature of disability and the discrimination that he was going to face for the rest of his life."
Globalize defends decision to stock 'Retarde' label in its stores
Clayton Cross, managing director for Globalize across South Australia and Victoria, has defended the company's decision to stock Art of Aztec's Retarde label in their stores.
"They're just some disgruntled mothers mollycoddling some children," he said.
"To be honest, I think everyone's got to harden up a little.
"If someone walks past you wearing a shirt with seven letters that don't actually mean anything and you're so insulted by it that you become aggrieved.
"You've really got to have a good hard look at yourself."
They may be disgruntled but these parents have intellectually and physically disabled children, and feel that is derogatory towards them; the word 'retard' is discriminatory.
In a statement, Adelaide designers Renae Beaty and Ema Raw, defended the spelling of the word 'Retarde'.
"We do not see why people would take offence, as this word is clearly not an English word. 'RETARDE' is a French verb used on our items, which means 'delayed' or 'held up'."
Paralympic cyclist wears 'Retarde' t-shirt, defends designers
Paralympic cyclist Mel Leckie turned up in her wheelchair at the Rundle Mall protest and defended the two designers by wearing one of their t-shirts.
"I don't understand what the problem is because it's not directed at a person or a group of people," she said.
"The only negative connotation is what society has put on it.
"If it was more specific as you're a retard, then I would understand."
However Dignity for Disability MP Kelly Vincent believes people need to be more thoughtful about the negative messages The Art of Aztec's clothing line conveys.
"I want people to actually think about what they're doing when they put that shirt on, what they're saying about themselves and about people they don't even know," he said.
"This isn't just about the people here today, it's about everyone who's been ridiculed at high school, everyone that's ever been put down for being different."
Globalize management says it will continue to stock the label, but won't ask for a recut of the Retarde line.
Topics: community-and-society, activism-and-lobbying, discrimination, health, disabilities, sa, adelaide-5000, australia
First posted


text:
Ski Data
Wax Book
Ralph's Blog
SRG News
About Us
We stock the highest quality equipment, clothing, wax and accessories that we use and believe in. These include equipment from Alpina, Atomic, Fischer, Jenex V2, Salomon and Swix. We stock activewear apparel from Bjorn Daehlie, Craft, Lill-Sport, Salomon, Swix, Turtle Fur, SportHill, Wigwam and Yoko. We can supply you with wax and accessories from Star, Start, Swix and Toko. Books and videos are available to give you tips on waxing and technique.
Questions about what skis to buy, how we fit skis, waxing information or how to dress will be answered by well informed technicians. Feel free to call 800 423-9730 or send us an email -- we will reply giving you accurate information.


text:
Item Name
Item Type
Polo shirt
Tee Shirt
Order By
Item Name
Price: Low to High
Price: High to Low
Show All > Other Publications
More information...
Food Carotenoids: Chemistry, Biology and Technology
by Delia Rodriguez-Amaya, 2015.
Medicinal Plant Research in Africa: Pharmacology and Chemistry
by Victor Kuete, 2013.
Plants, People, and Culture: The Science of Ethnobotany
by Michael J. Balick & Paul Alan Cox, 2005.
Rhodiola rosea
by Alain Cuerrier and Kwesi Ampong-Nyarko, 2014.
American Botanical Council, 6200 Manor Rd, Austin, TX 78723 Phone: 512-926-4900 | Fax: 512-926-2345 | Email: firstname.lastname@example.com
The information on this site is intended for educational purposes only and is not a substitute for the advice of a qualified healthcare professional. The American Botanical Council does not endorse or test products, nor does it verify the content or claims made, either implicit or explicit. ABC does not accept responsibility for the consequences of the use of this information or its most up-to-date accuracy. ABC is an independent, nonprofit, tax-exempt research and education organization under IRS section 501(c)(3). All text, images and content Copyright © 2016 American Botanical Council, unless otherwise noted.


text:
Assume that you have a mix of circles, stars and squares pretty much like the image shown below.
Now, let's say that you want to change the color of all the stars from amber to red. One way to do this, would be to select all the stars with the selection tool one by one while holding down the SHIFT key, and change the color to red.
Instead of doing just that... let's have a look on a more clever way to work and see how you can save your selections so you can quickly reuse them at other stages of the design thus saving you time.
So select all the stars, anyway you want and then go to the Select menu and choose Save selection... Now give a name to that selection. I used stars.
Great... Deselect the stars, and repeat the same procedure with the green circles. Name this second selection green circles. Now, if you did everything correctly, by clicking on the Select menu you should see your two saved selections at the bottom of the drop down menu.
So now let's say you deselect everything. if you want to change the stars fill color, just click and load the stars selection you created and saved earlier.
Do you perhaps want to change the green circles stroke? Piece of cake... Load the green circles selection and make it e.g. thicker.
Another cool characteristic of this feature is that if you save and close the file and come back a couple of days later, your selections will still be there for future reference. If you decide you no longer need one of the selections, you can easily click on the Select menu and choose edit selection. Click from the list on the selection you no longer need, press Delete and OK. The selection is gone.
When working with complicated designs that consist of many objects and shapes, saving the selections you frequently use, can prove extremely useful and saves you precious 'creative' time.
Thank you very much...
Related posts I think you should like...
1. Selection Tools
2. The Pathfinder Panel, PART 1
3. The Pathfinder Panel PART 2